Related references
Note: Only part of the references are listed.Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Hengwei Wu et al.
JAMA NETWORK OPEN (2021)
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide
Jiao-Yu Zhao et al.
ANNALS OF HEMATOLOGY (2021)
Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease
Christopher Streiler et al.
BONE MARROW TRANSPLANTATION (2020)
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
Virginia Esamilla Gomez et al.
BONE MARROW TRANSPLANTATION (2020)
Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults
I. S. Moiseev et al.
BONE MARROW TRANSPLANTATION (2020)
How I treat steroid-refractory acute graft-versus-host disease
Paul J. Martin
BLOOD (2020)
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Madan Jagasia et al.
BLOOD (2020)
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Olaf Penack et al.
Lancet Haematology (2020)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease
Badri Modi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
How I treat refractory chronic graft-versus-host disease
Stefanie Sarantopoulos et al.
BLOOD (2019)
Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation
Sameem Abedin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results
Martay Gonzalez Vicent et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment
Helene M. Schoemans et al.
BONE MARROW TRANSPLANTATION (2018)
Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center
Aliana Meneses Ferreira et al.
BONE MARROW TRANSPLANTATION (2018)
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease
Hanna Jean Khoury et al.
BONE MARROW TRANSPLANTATION (2018)
Classification systems for chronic graft-versus-host disease
Stephanie J. Lee
BLOOD (2017)
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease
C. Hurabielle et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Mauricio Sarmiento Maldonado et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients
Pooja Khandelwal et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report
Stephanie J. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R. Zeiser et al.
LEUKEMIA (2015)
Share Paper
